Treatment of metastatic prostate cancer: Lessons from the androgen receptor

Hematology/Oncology Clinics of North America

Volumn 10, Issue 3, 1996, Pages 713-725

  Bubley, G J ^a   Balk, S P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; DIETHYLSTILBESTROL; GONADORELIN AGONIST; KETOCONAZOLE;

ADRENALECTOMY; CANCER HORMONE THERAPY; CANCER SURVIVAL; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR DENSITY; REVIEW; TREATMENT OUTCOME;

EID: 0029905257     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70363-4     Document Type: Article

References (55)

1. K. Akakura N. Bruchovsky S.L. Goldenberg Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen Cancer 71 1993 2782
2. M. Beato Gene regulation by steroid hormones Cell 56 1989 335
3. G. Blackledge Casodex—mechanisms of action and opportunities for usage Cancer 72 1993 3830
4. C.C. Boring T.S. Squires T. Tong Cancer statistics, 1994 CA Cancer J Clin 44 1994 7
5. W. Bourguet M. Ruff P. Chambon Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha Nature 375 1995 377
6. D.P. Byar D. Corle Hormone therapy for prostate cancer: Results of the VACURG studies [abstract] 7 1988 165
7. W.J. Catalona Management of cancer of the prostate N Engl J Med 331 1994 996
8. A.Y. Chang J.M. Bennett K.J. Pandya A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate carcinoma Am J Clin Oncol 12 1989 358
9. J.C. Chen R.M. Evans A transcriptional co-repressor that interacts with nuclear hormone receptors Nature 377 1995 4544
10. E.D. Crawford M.A. Eisenberger D.G. McLeod A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321 1989 419
11. Z. Culig A. Hobisch M.V. Cronauer Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone Mol Endocrinol 7 1993 1541
12. A. De Bellis C.A. Quigley N.F. Cariello Single base mutations in the human androgen receptor gene causing complete androgen insensitivity: Rapid detection by a modified denaturing gradient gel electrophoresis technique Mol Endocrinol 6 1992 1909
13. R. De Coster M.C. Coene C. Haelterman Effects of high-dose ketoconazole treatment on adrenal mineralocorticoid biosynthesis in dogs and rats Acta Endocrinol 115 1987 423
14. R.N. Dexter L.M. Fishman R.L. Ney Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: Studies of the mechanism of action J Clin Endocrinol Metab 27 1967 473
15. H.F. English N. Kyprianou J.T. Isaacs Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration Prostate 15 1989 233
16. W.D. Figg A.O. Sartor A. Thibault The in vitro response of four antisteroid receptor agents on the hormone-responsive prostate cancer cell line LNCaP [abstract A1629] Proc Annu Meeting Am Assoc Cancer Res 1994
17. W.D. Figg O. Sartor M.R. Cooper Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer Am J Med 98 1995 412
18. S.D. Fossa G. Hosbach E. Paus Flutamide in hormone-resistant prostatic cancer J Urol 144 1990 1411
19. J. Geller Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer Semin Oncol 12 1985 28
20. J. Geller Basis for hormonal management of advanced prostate cancer Cancer 71 1993 1039
21. J.E. Griffin Male reproductive function J.E. Griffin S.R. Ojeda Textbook of Endocrine Physiology 1988 Oxford University Press New York 165
22. S.J. Harland G.M. Duchesne Suramin and prostate cancer: The role of hydrocortisone Eur J Cancer 28A 1992 1295
23. R.A. Hiipakka S. Liao Androgen physiology: Androgen receptors and action L.J. Degroot Endocrinology ed 3 1995 WB Saunders Philidelphia
24. A. Hobisch Z. Culig C. Radmayr Distant metastases from prostatic carcinoma express androgen receptor protein Cancer Res 55 1995 3068
25. J.S. Horoszewisz S.S. Leong E. Kawanski LNCaP model of prostatic carcinoma Cancer Res 43 1983 1809
26. C. Huggins C.V. Hodges Studies on prostatic cancer: Effect of castration, of estrogen and androgen injections on serum phosphatases in metastatic prostatic carcinoma of the prostate Cancer Res 1 1941 293
27. C. Huggins W. Scott Bilateral adrenalectomy in prostatic cancer. Clinical features and excretion of 17-ketosteroids and estrogen Ann Surg 122 1945 1031
28. J. Imperato-McGinley T. Gautier Inherited 5 alpha-reductase deficiency in man Trends Genet 2 1986 130
29. J.T. Isaacs N. Kyprianou Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer Urol Res 15 1987 133
30. G. Jenster H.A. van der Korput C. van Vroonhoven Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization Mol Endocrinol 5 1991 1396
31. S. Liao Molecular actions of androgens G. Litwack Biochemical Actions of Hormones 1977 Academic Press New York
32. C. Liebertz W.K. Kelley M. Theodoulou High dose Casodex for prostate cancer: PSA declines in patients with flutamide withdrawal responses. [abstract] Proc Am Soc Clin Oncol 14 1995 232
33. D.B. Lubahn T.R. Brown J.A. Simental Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity Proc Natl Acad Sci USA 86 1989 9534
34. D.B. Lubahn D.R. Joseph M. Sar The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate Mol Endocrinol 2 1988 1265
35. C. Mahler J. Verhelst L. Denis Ketoconazole and liarozole in the treatment of advanced prostatic cancer Cancer 71 1993 1068
36. M. Marcelli W.D. Tilley C.M. Wilson Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: Premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance Mol Endocrinol 4 1990 1105
37. F.J. Mayer E.D. Crawford The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy Urol Clin North Am 21 1994 707
38. J.D. McConnell Physiologic basis of endocrine therapy for prostatic cancer Urol Clin North Am 18 1991 1
39. T.J. McDonnell P. Troncoso S.M. Brisbay Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940
40. D.G. McLeod Antiandrogenic drugs Cancer 71 1993 1046
41. J.R. Newmark D.O. Hardy D.C. Tonb Androgen receptor gene mutations in human prostate cancer Proc Natl Acad Sci USA 89 1992 6319
42. J.A. Ruizeveld de Winter P.J. Janssen H.M. Sleddens Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer Am J Pathol 144 1994 735
43. J.A. Ruizeveld de Winter J. Trapman M. Vermey Androgen receptor expression in human tissues: An immunohistochemical study J Histochem Cytochem 39 1991 927
44. P. Schellhammer R. Sharifi N. Block A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group Urology 45 1995 745
45. H.I. Scher W.K. Kelly Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer J Clin Oncol 11 1993 1566
46. J.A. Simental M. Sar M.V. Lane Transcriptional activation and nuclear targeting signals of the human androgen receptor J Biol Chem 266 1991 510
47. E.J. Small P.R. Carroll Prostate-specific antigen decline after Casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome Urology 43 1994 408
48. H. Suzuki N. Sato Y. Watabe Androgen receptor gene mutations in human prostate cancer J Steroid Biochem Mol Biol 46 1993 759
49. H. Takahashi M. Furusato W.C. Allsbrook Jr Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men Cancer Res 55 1995 1621
50. I. Tannock M. Gospodarowicz W. Meakin Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 1989 590
51. M.E. Taplin G.J. Bubley T.D. Shuster Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 1995 1393
52. W.D. Tilley C.M. Wilson M. Marcelli Androgen receptor gene expression in human prostate carcinoma cell lines Cancer Res 50 1990 5382
53. F.M. Torti B.L. Lum R. Lo Tamoxifen in advanced prostatic carcinoma. A dose escalation study Cancer 54 1984 739
54. P.A. Wingo T. Tong S. Bolden Cancer statistics, 1995 CA Cancer J Clin 45 1995 8
55. J. Younge J. Appel K. Bergsman Prolonged remissions with aminoglutethimide in advanced prostate cancer [abstract] Proc Am Soc Clin Oncol 11 1992 211